Pfizer submits new drug application to FDA for its COVID-19 treatment Paxlovid
Pfizer announced this morning it submitted a new drug application to formally ask the U.S. Food and Drug Administration for full approval of its COVID-19 treatment Paxlovid for patients who are at high risk for progression to severe illness from the virus.
•
Jun 30, 2022, 11:36 AM
•
Updated 910 days ago
Share:
More Stories
1:08
The day after Christmas: Hudson Valley shoppers flock to malls for returns
4h ago1:37
Friday's Mega Millions drawing offers estimated $1.15 billion jackpot
9h ago1:26
Last-minute holiday shoppers visit The Westchester Mall for the perfect gift
2ds ago1:11
Last-minute holiday shopping in full swing at Hudson Valley malls
3ds ago2:03
KIYC: Retailers crack down on return fraud amid expected $150 billion in holiday returns
3ds ago0:21
FDA: More than 2 million cans of Jarritos Coconut Water recalled over seal concerns
6ds ago1:08
The day after Christmas: Hudson Valley shoppers flock to malls for returns
4h ago1:37
Friday's Mega Millions drawing offers estimated $1.15 billion jackpot
9h ago1:26
Last-minute holiday shoppers visit The Westchester Mall for the perfect gift
2ds ago1:11
Last-minute holiday shopping in full swing at Hudson Valley malls
3ds ago2:03
KIYC: Retailers crack down on return fraud amid expected $150 billion in holiday returns
3ds ago0:21
FDA: More than 2 million cans of Jarritos Coconut Water recalled over seal concerns
6ds agoPfizer announced this morning it submitted a new drug application to formally ask the U.S. Food and Drug Administration for full approval of its COVID-19 treatment Paxlovid for patients who are at high risk for progression to severe illness from the virus.
The submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals.
Paxlovid is currently authorized for emergency use for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients, 12 years and older, with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
The submission provides the longer-term follow-up data necessary for acceptance and potential approval.
More from News 12
0:22
Cold Spring Village Hall closed due to COVID-19 surge and staff shortages
Hometown Heroes in the Hudson Valley
1:28
Medical experts recommend to still take precautions following CDC's revised COVID isolation guidelines
1:52
Judge: 3 men convicted in COVID-19 relief aid fraud
1:47
Wondrous Things store in Briarcliff Manor to close after 34 years; everything 25% off
0:28
